Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1908-1909 in allergic rhinitis
NCT02127801Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in allergic rhinitis (AR) comparing REGN1908-1909 with Placebo (2 arms). Primary endpoint: Change in allergic symptom scale score at Day 8. Started Oct 2014; status: completed.
02
Drugs
freneslerbartmevonlerbart
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02127801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127801.